Bus satisfaction in England increases after ‘positive changes'
Passenger satisfaction with buses in England outside London increased last year after 'positive changes', according to a survey.
Watchdog Transport Focus said overall satisfaction in 2024 was 83%, up from 80% in 2023.
It said 'significant' investment' as part of bus service improvement plans and a fares cap 'appears to be having an impact'.
Both policies were introduced under the Conservative government.
Passengers in the Derby City area were the most satisfied with their journey, with a score of 92%.
Those in West Yorkshire were for the least satisfied (77%) for the second year in a row.
East Sussex and Warrington were two of the most improved areas, both up eight percentage points to 87% and 85% respectively.
Transport Focus surveyed 41,000 passengers across 39 areas in England outside London, covering issues such as the onboard experience, punctuality, value for money and journey times.
Louise Collins, director of Transport Focus, said: 'The positive changes seen across bus services in England have boosted overall passenger satisfaction.
'The changes show how Government funding, hard work from local authorities and operators, and listening to what passengers want can improve journeys.
'The wide variation in scores at a local level in the survey shows that some passengers still aren't getting the bus service they should.'
Local transport minister Simon Lightwood said the survey shows that 'councils are putting bus service funding to good use'.
He went on: 'Our Bus Services Bill will hand control back for local leaders to operate services, and it's great to see areas like Nottingham where councils operate their own services, scoring higher than average satisfaction rates.
'Alongside nearly £1 billion to enhance service frequencies, improve bus stop infrastructure and boost the comfort and accessibility of services, we're backing our buses like never before, and I'm excited to see how this will continue to grow customer satisfaction and make our bus services even more attractive.'
Graham Vidler, chief executive of Confederation of Passenger Transport, which represents bus and coach operators, said: 'It's fantastic to see bus passenger satisfaction on the rise – a testament to the excellent partnerships between bus operators and local authorities in many parts of the country and the dedication of everyone working in the industry.
'We want every passengers to be satisfied with their journey and with significant changes ahead for the bus industry, including the Bus Services (No.2) Bill and the impact of Government spending decisions, we urge policymakers to prioritise passengers, ensuring even greater satisfaction and better services in the year ahead.'
The Labour Government increased the cap on single bus fares in England from £2 to £3 on January 1.
Funding for bus services comes from many different pots of money, including some available for operators and others set aside for local authorities.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
7 minutes ago
- Associated Press
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine – – VERITAC-2 data support vepdegestrant as a potential treatment option in patients with ESR1m ER+/HER2- advanced or metastatic breast cancer – NEW HAVEN, Conn., June 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with its partner Pfizer Inc. (NYSE: PFE), for vepdegestrant for the treatment of patients with ER-positive (ER+)/human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-) ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. This submission is based on results from VERITAC-2 (NCT05654623), a global, randomized Phase 3 trial evaluating vepdegestrant versus fulvestrant. 'This milestone comes after an exciting presentation at the American Society of Clinical Oncology's annual meeting,' said John Houston, Ph.D., Chairperson, Chief Executive Officer and President at Arvinas. 'We look forward to the NDA review and to the first ever FDA-approved PROTAC ER degrader potentially being available to patients who could benefit from a much needed, new treatment option.' Vepdegestrant is being jointly developed by Arvinas and Pfizer for the treatment of patients with advanced or metastatic ER+/HER2- breast cancer and was granted fast track designation as a monotherapy by the FDA. Results from the VERITAC-2 study were recently presented in a late-breaking oral presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting and were selected for the ASCO press briefing and for Best of ASCO. Detailed results were also simultaneously published in the New England Journal of Medicine. About the VERITAC-2 Clinical Trial The Phase 3 VERITAC-2 clinical trial ( NCT05654623 ) is a global, randomized trial evaluating the efficacy and safety of vepdegestrant (ARV-471) as a monotherapy compared to fulvestrant in patients with ER+/HER2- advanced or metastatic breast cancer. The trial enrolled 624 patients at sites in 25 countries who had previously received treatment with a CDK4/6 inhibitor plus endocrine therapy. Patients were randomized 1:1 to receive either vepdegestrant once daily, orally on a 28-day continuous dosing schedule, or fulvestrant, administered intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each 28-day cycle starting from Day 1 of Cycle 2. In the trial, 43% of patients (n=270) had ESR1 mutations detected. The primary endpoint was progression-free survival (PFS) in the ESR1-mutation and intent-to-treat populations as determined by blinded independent central review. Overall survival is the key secondary endpoint. About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROTAC (PROteolysis TArgeting Chimera) protein degrader designed to specifically target and degrade the estrogen receptor (ER). Vepdegestrant is being developed as a potential monotherapy for ER+/HER2- advanced or metastatic breast cancer with estrogen receptor 1 (ESR1) mutations in the second line-plus setting. In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs, commercialization expenses, and profits. The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy. About Arvinas Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit and connect on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: the NDA review and to the first ever FDA-approved PROTAC ER degrader potentially being available to patients who could benefit from a much needed, new treatment option; and vepdegestrant's development as a potential monotherapy for ER+/HER2- advanced or metastatic breast cancer with ESR1 mutations in the second line-plus setting. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas' strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'target,' 'goal,' 'potential,' 'will,' 'would,' 'could,' 'should,' 'look forward,' 'continue,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas and Pfizer will successfully perform their respective obligations under the collaboration between Arvinas and Pfizer; whether Arvinas and Pfizer will be able to successfully conduct and complete clinical development for vepdegestrant as a monotherapy; whether the VERITAC-2 clinical trial will meet the secondary endpoint for overall survival; risks related to our expectations regarding the potential clinical benefit of vepdegestrant to patients; uncertainties relating to regulatory applications and related filing and approval timelines, including the New Drug Application seeking FDA approval of vepdegestrant and the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; whether FDA or other regulatory authorities will require additional information or further studies, or may fail or refuse to approve or may delay approval of vepdegestrant; whether Arvinas and Pfizer, as appropriate, will be able to obtain marketing approval for and commercialize vepdegestrant and other product candidates on current timelines or at all; Arvinas' ability to protect its intellectual property portfolio; Arvinas' reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas' cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the 'Risk Factors' section of Arvinas' Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas' current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas' views as of any date subsequent to the date of this release. Contacts Investors: Jeff Boyle +1 (347) 247-5089 [email protected] Media: Kirsten Owens +1 (203) 584-0307 [email protected]
Yahoo
40 minutes ago
- Yahoo
Most new homes must have solar panels and heat pumps under Government proposals
Builders will be required to fit solar panels on rooftops and install low-carbon heating for most new build homes in England under proposed changes to be published this year. The Energy Department (Desnz) said on Friday that the future homes standard (FHS), which will be published in autumn, is expected to require new residential properties to have solar panels by default. Gas boilers will also not meet the proposed standard, meaning low-carbon heating – such as heat pumps – will also likely become the new default under building regulations. With a significant amount of the UK's carbon footprint coming from gas heating of homes, the FHS will require new housing in England to produce fewer carbon emissions than those built under current regulations. The Government said the measures will also help to slash household energy bills and boost the nation's energy security. Energy Secretary Ed Miliband said: 'Solar panels can save people hundreds of pounds off their energy bills, so it is just common sense for new homes to have them fitted as standard. 'So many people just don't understand why this doesn't already happen. With our plans, it will.' Desnz calculates that a typical existing UK home could save around £530 a year from installing rooftop solar based on the current energy price cap. Matthew Pennycook, housing and planning minister, said: 'The future homes standard will ensure new homes are modern and efficient with low-carbon heating, while our common-sense planning changes will now make it easier and cheaper for people to use heat pumps and switch to EVs so they can play their part in bolstering our nation's energy security.' Current building regulations do not require developers to add solar panels or heat pumps to new homes. In 2023, the previous Conservative government proposed new build homes would need solar panel coverage equivalent to 40% of the building's floor area. But this also allowed for exemptions, which would lead to no solar on many developments, the current Government says. Under the proposed changes, developers who cannot meet 40% coverage will still be required to install a reasonable amount of solar coverage – or other forms of renewable electricity generation, with rare exceptions. Ministers also say the FHS will effectively require low-carbon heating, such as domestic heat pumps installed into new builds. The previous Conservative government faced criticism for rowing back on its proposals to ban the sale of new gas boilers by 2035. While the Government is not planning to introduce such a ban, citing concerns around cost, Desnz confirmed on Friday that FHS proposals include mandating minimum criteria for energy efficiency which mean newly built homes have to install greener heating systems. Recent changes to planning rules aimed at removing barriers to heat pump installations came into force on May 29, enabling households to install a heat pump within one metre of their property's boundary without having to submit a planning application. The first quarter of 2025 saw a record number of applications to the boiler upgrade scheme, which provides households with up to £7,500 off the cost of a heat pump, seeing a 73% jump from the same quarter last year. Charles Wood, deputy director of policy (systems) at Energy UK, said: 'This change, alongside wider reforms to planning processes and network connections, will reduce bills for people in new build properties while also giving the industry confidence to invest in increased manufacturing and installer training as demand increases, creating jobs and bringing down technology costs for everyone.' The UK is legally committed to reaching its net zero target by 2050, meaning the UK must cut carbon emissions until it removes as much as it produces, in line with the 2015 Paris Climate Agreement.
Yahoo
an hour ago
- Yahoo
Brace yourself for Rachel Reeves's most cynical tax raid yet
Cast your mind back to little over a year ago when Sir Keir Starmer and Rachel Reeves came into power and suddenly became very sombre about the state of the nation's finances. Starmer warned that 'things are worse than we ever imagined', and said that the October Budget would be 'painful'. Despite a £40bn tax raid in the Chancellor's maiden Budget, things are still, it appears, just as bleak. Reeves's economic blunders have helped create a funding void that economists warn could require a £30bn tax raid to fill. But still, Labour has doubled down on its naive manifesto pledge not to raise income tax, National Insurance or VAT. So if the Chancellor won't tax 'workers', who will she go after? I'm afraid it's bad news for pensioners and anyone who might be perceived as wealthy. Labour has now reluctantly announced a partial U-turn on its foolish decision to take the winter fuel allowance from 10 million pensioners in an effort to save £1.5bn a year. The Treasury is now reportedly drawing up plans to hand back the payments to lower-income pensioners. I suspect Labour will use the return of the winter fuel payment to justify a tax raid on wealth and retirement income. You want the return of the winter fuel allowance? Well, you'll have to pay for it. Bound by its election pledge, Labour will not be asking workers to pay for it. Instead, what we can expect are more backdoor tax grabs and insidious stealth rises. These will be, for all intents and purposes, tax rises that ultimately hurt households. Angela Rayner's demands to force more of us to pay the 45p in the pound rate of income tax and to reinstate the pension lifetime allowance can surely not be off the table. The Tory deep freeze on tax rates across the board will almost certainly be extended, dragging more workers and pensioners into higher tax brackets that consume more of their wealth. Aspiration and prudence will ultimately be the victims of this relentless tax drive that now means hard work no longer pays. The Government has already shown that it holds ideology above reason. Its capital gains tax raid will blow a £23bn hole in the public purse. Its inheritance tax assault on farmers risks a food crisis and will also cost the Treasury £2bn. Its vindictive attack on private schools is already proving to be a bad idea, and its talk of taxing the wealthy has triggered an exodus of millionaires whose taxes we desperately need. Fresh tax rises are only inevitable because of Labour's mismanagement of the economy. It has splurged on the wasteful public sector and punished the productive private sector. Now it is throwing billions at the North because it is scared of Reform UK. We can only hope that the Government has learnt lessons from its early months in power and will start to undo the damage. The winter fuel U-turn suggests so, but its blind stubbornness over farmers and blinkered tax pursuit of hard-earned wealth suggests otherwise. If the economy does improve, Labour needs to rescind its tax grabs and incentivise money-making and growth. It's patently obvious that you cannot tax your way to prosperity. Britain can hardly afford to have a Chancellor who is learning on the job. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
